Feds Eye Partial Pretrial Ruling In Regeneron FCA Case

The government has urged a Massachusetts federal judge to rule that Regeneron Pharmaceuticals "naturally or foreseeably" caused providers to present false claims for its macular degeneration drug Eylea, arguing that it...

Already a subscriber? Click here to view full article